Launching the GLADEL 2.0 Study Group
GLADEL has more than 20 years of sustained work with a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region.
A new generation of “Lupus Investigators” throughout Latin America launched a novel study that aim to identify subgroups of patients with SLE, based on demographic and clinical profile, serum and urinary biomarkers and transcriptome studies using blood and tissue RNA to identify potential transcriptional signatures.
This study is supported and funded by Janssen Research & Development, LLC.
GLADEL 2.0 Cohort. Study design.
- ~150 investigators
- 42 centers
- 10 countries
- 2,100 individuals
- 1,050 SLE patients
- 1,050 controls (healthy non-relative control at ratio 1:1, matched by age (± 5 years), sex and ethnic group)
- +500 variables (sociodemographic, clinical and patients reported outcomes)
- Centralize analysis of:
- Serological biomarkers
- Urinary biomarkers